Dr. Jean-Marie Cuillerot, MD appointed CMO for Dragonfly Therapeutics

Dragonfly Therapeutics welcomes on board Dr. Jean-Marie Cuillerot, MD as its Chief Medical Officer. Dr. Cuillerot set to spearhead clinical development of Dragonfly’s natural Killer cell-based  immunotherapies. He brings with him nearly 20 years of experience in drug development and 15 years of unique experience in immunotherapy. At BMS, Dr. Jean-Marie Cuillerot was the Medical Lead for Ipilimumab Life Cycle Management, developing the company’s anti-CTLA-4 antibody as a treatment for lung cancer, castrate resistant prostate cancer, ovarian cancer, gastric cancer and adjuvant melanoma, and leading the execution of many of its critical clinical studies.  In this role, he supported the filing activities of Iipilimumab, the world’s first immune checkpoint therapy for cancer.

Bill Haney, co-founder and CEO of Dragonfly Therapeutics said “As a pioneering clinician who helped drive the first immunotherapries to patients, his talent will be invaluable in achieving our shared goal of rapidly providing cancer-curing therapies for the millions of patients that are still not served by immunotherapy.”

Dr. Tyler Jacks, co-founder of Dragonfly and Director of MIT’s Koch Institute of Intergrative Cancer Research claimed “while simultaneously providing drug candidates to our pharma partners on a similar trajectory.  Jean-Marie’s experience leading first in class candidates successfully and rapidly through the clinic speaks to his deep understanding of both the needs of patients and those of the regulatory agencies.  I’m very excited to be working together with him on Dragonfly’s team.”